Prospective Cohort Study on Tolerability & Safety of Uro-Tainer® Polihexanide 0.02%

Inclusion Criteria: * Patients with a sustained pain sensation in the bladder (for the first five patients). * Patients staying as inpatients with long-term (\> 2 weeks) urethral or suprapubic catheters. * Age \> 18 years * Ability to read, write and speak German or French * Women of child bearing potential must test negative on standard urine pregnancy test two weeks prior to the start of the study and must agree to practice appropriate contraceptive methods until the end of the study (e.g. oral contraceptive, IUD, intra-muscular contraceptive, abstinence). * Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent approved by the cantonal Ethics Committee (IEC) prior to all evaluations Exclusion Criteria: * Symptomatic UTI * Hematuria * Fever (tympanic temperature \> 38.5°C) * Surgical intervention to genito-urinary tract in the last 6 months * Patients receiving any other concurrent catheter irrigation * Known allergy or sensitivity to any of the ingredients in Uro-Tainer® Polihexanide 0.02% * Known allergy or sensitivity to chlorhexidine * Pregnancy or Lactation * Simultaneous participation in another interventional trial * Administration of any other catheter irrigation 1 week prior to study * Administration of any of the following medications 4 weeks prior to study entry, unless they have been used at a stable regimen : antibiotics, antipyretics, antihistamines, medications susceptible to cause an autonomic response or to mask an allergic reaction. * For the first five patients: impaired pain sensation in the bladder for the first five patients: Administration of any antipyretics and analgesic.